Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Sopheon Terug naar discussie overzicht

Sopheon november 2018

87 Posts
Pagina: 1 2 3 4 5 »» | Laatste | Omlaag ↓
  2. marblesthegame 31 oktober 2018 19:09

    • marblesthegame

      Lid sinds: 06 jul 2005

      Laatste bezoek: 28 apr 2024

    • Aanbevelingen

      Ontvangen: 355

      Gegeven: 722

    •    Aantal posts: 1.442

    Sopheon PLC
    Issue of Equity
    RNS Number : 9397F
    Sopheon PLC
    31 October 2018

    For immediate release


    SOPHEON PLC
    ("Sopheon" or the "Company")


    Issue of Equity


    Sopheon (LSE: SPE), the international provider of software and services for complete Enterprise Innovation Management solutions, announces that, following the exercise of options by an employee, it has issued and allotted 1,750 new ordinary shares of 20 pence each in the Company ("Ordinary Shares"). Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 6 November 2018.



    The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. The total number of Ordinary Shares in issue following Admission will be 10,134,141. The Company does not hold any shares in treasury. Accordingly, the figure of 10,134,141 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
  3. [verwijderd] 2 november 2018 08:28

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    SOPHEON PLC
    01/11/2018 | Press release | Distributed by Public on 01/11/2018 20:25
    How Smart Are Your Documents?
    One of the main barriers to the successful deployment of enterprise software applications is user adoption. Not only because companies want their employees to have a good user experience using the software, but also to ensure that the company realizes the hoped-for benefits that drove the investment to begin with.
    In the case of Sopheon's Accolade® software, one of the common benefits most customers want to get value from as quickly as possible is having a 'single source of truth' - a repository of up-to-date, trusted data - on which they can confidently base some of their most mission-critical decisions.
    One of the ways that we are helping our customers achieve this is by providing a deep integration between our software and Microsoft® Office tools. Why, you ask? Well, are you aware that there were 1.2 billion Microsoft Office users in 20161? One can only assume that today that figure would be even higher.
    Our thinking has always been that to get the information that folks are generating as part of their everyday work into the Accolade software, we had to make sure our software could capture the data when and where it is being generated. So as far back as 2005 we were the first to introduce a smart technology to the enterprise software market that was the forerunner of the deep and robust Microsoft Office integration that Accolade offers today.
    The Smart Document integration allows team members the freedom to work in Accolade or in a standard Microsoft document environment, according to personal preference. Users can create and update data, as well as report on it, using familiar Microsoft applications, and with a single click save it to the Accolade system.
    It helps our customers be more efficient and productive with their innovation and new product development (NPD) work, and helps them achieve that real-time (or near-real-time) accuracy they are so keen to have.

    Trinko
  6. Gartje 7 november 2018 15:07

    • Gartje

      Lid sinds: 26 aug 2016

      Laatste bezoek: 23 feb 2024

    • Aanbevelingen

      Ontvangen: 56

      Gegeven: 1

    •    Aantal posts: 955

    Lijkt? Ze beginnen pas met groeien, geduld hebben en rustig achterover leunen en weten dat de cijfers over 2018 weer dusdanig zullen zijn dat er zeker een stijging in moet zitten! Het gaat de goede kant op;-))))
  11. Gartje 8 november 2018 13:15

    • Gartje

      Lid sinds: 26 aug 2016

      Laatste bezoek: 23 feb 2024

    • Aanbevelingen

      Ontvangen: 56

      Gegeven: 1

    •    Aantal posts: 955

    Is iedereen flauw gevallen;-))) en wie is er nog aan boord? Op naar de 15 pond mensen
  13. Gartje 8 november 2018 13:29

    • Gartje

      Lid sinds: 26 aug 2016

      Laatste bezoek: 23 feb 2024

    • Aanbevelingen

      Ontvangen: 56

      Gegeven: 1

    •    Aantal posts: 955

    Ik denk een stijging van de koers;-))) en na de laatste update zitten die goede cijfers er zeker in!
  17. woutje. 8 november 2018 18:20

    • woutje.

      Lid sinds: 25 aug 2016

      Laatste bezoek: 24 jul 2022

    • Aanbevelingen

      Ontvangen: 9

      Gegeven: 1

    •    Aantal posts: 43

    Ik hou ze vast ondanks het enorme rendement dat ik al heb, heb ze nog uit de beginperiode en ik wacht tot een pond of 20. Dan bekijk ik wat vooruitzichten zijn en verkoop ze wellicht. Vasthouden doe ik dan bij nog altijd flinke toename van de omzet en klanten. Natuurlijk ook afhankelijk van uitbetaling vxn dividend maar daar verwacht ik niet dat we snel bij een pond komen.
87 Posts
Pagina: 1 2 3 4 5 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.285
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 46.355
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.904
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.377
Aedifica 2 829
Aegon 3.257 320.055
AFC Ajax 537 7.018
Affimed NV 2 5.752
ageas 5.843 109.778
Agfa-Gevaert 13 1.859
Ahold 3.536 73.981
Air France - KLM 1.024 34.315
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.771
Alfen 12 16.346
Allfunds Group 3 1.196
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 335
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.484 114.757
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.820 240.260
AMG 965 125.727
AMS 3 73
Amsterdam Commodities 303 6.520
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.115
Apollo Alternative Assets 1 17
Apple 5 313
Arcadis 251 8.615
Arcelor Mittal 2.023 318.602
Archos 1 1
Arcona Property Fund 1 266
arGEN-X 15 9.106
Aroundtown SA 1 176
Arrowhead Research 5 9.273
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.681
ASML 1.762 76.930
ASR Nederland 18 4.122
ATAI Life Sciences 1 7
Atenor Group 1 333
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.650
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.667

Macro & Bedrijfsagenda

  1. 29 april

    1. NL producentenvertrouwen april
    2. Philips Q1-cijfers
    3. Fra BBP eerste kwartaal (voorlopig)
    4. AkzoNobel €1,54-ex-dividend
    5. Besi €2,15 ex-dividend
    6. Fugro €0,40 ex-dividend
    7. Heineken €1,04 ex-dividend
    8. Vastned €1,28 ex-dividend
    9. CTP €0,275 ex=dividend
    10. EU consumentenvertrouwen april (definitief)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda